Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.36 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23532125 | 1.00 | L3MBTL4 (0.36) | L3MBTL4L3MBTL3L3MBTL1CRBNKDM4E | |
| SCHEMBL23532161 | 0.90 | SMYD3 (0.34) | CRBNKDM4EALDH1A1DDB1 | |
| SCHEMBL30160267 | 0.90 | SMYD3 (0.34) | CRBNKDM4EALDH1A1DDB1 | |
| SCHEMBL23531925 | 0.89 | ALDH1A1 (0.34) | CRBNALDH1A1DDB1OPRK1KMT2A | |
| SCHEMBL23532172 | 0.88 | CRBN (0.33) | CRBNDDB1 | |
| SCHEMBL18903202 | 0.86 | KDM4E (0.35) | L3MBTL4L3MBTL3L3MBTL1CRBNKDM4E | |
| SCHEMBL23532067 | 0.86 | FAAH (0.36) | — | |
| SCHEMBL25198512 | 0.86 | FAAH (0.36) | — | |
| SCHEMBL30304205 | 0.85 | CRBN (0.35) | CRBNALDH1A1DDB1 | |
| SCHEMBL23532103 | 0.85 | CRBN (0.34) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473283-B2 | Compounds and their use | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2025-11-18 | — | — | US | disclosed |
| US-20240317740-A1 | NOVEL COMPOUNDS AND THEIR USE | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2024-09-26 | — | — | US | disclosed |
| EP-4077324-A1 | NOVEL COMPOUNDS AND THEIR USE | Debiopharm International SA (CH) | 2022-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317740-A1 | NOVEL COMPOUNDS AND THEIR USE | PGLS, LSS, LAS1L | L3MBTL4 387/4885L3MBTL3 311/4885L3MBTL1 237/4885 |
| US-12473283-B2 | Compounds and their use | LSS, PGLS, LDHB | L3MBTL4 235/4885L3MBTL3 152/4885L3MBTL1 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.